A Virtual Pharma Organization



A Virtual Pharma Organization

With private funding and Duke’s help, Roses focuses on discovery and development. 

June 10, 2008 | Last year, Allen Roses left his position as senior vice president, pharmacogenetics, at GlaxoSmithKline to return to Duke University Medical Center, where he is director of the Duke Drug Discovery Institute (and Jefferson-Pilot Professor of Neurobiology and Genetics and a member of the Duke Institute for Genome Sciences and Policy). Ricki Lewis caught up with Roses, who keynoted Bio-IT World Expo in 2006 (See “Personalized Medicine’s Rosy Picture,” Bio-IT World, May 2006), to review pharma’s approach to genome-wide screening, his new freedoms back in academia, and the latest on pharmacogenomics and Alzheimer’s research.

Bio-IT World: How is the pharmaceutical industry using genome-wide association studies (GWAS)?
Roses: Genome wide screening for pharma will be most important in confirming candidate gene variants that differentiate patients with efficacy, using the particular end-points of the clinical trial. This is most important at the critical proof-of-concept (POC) step. Let’s say a molecule has made it through preclinical safety and first time in humans. The first efficacy indication would come from a small Phase IIA trial, then a larger Phase IIB proof of efficacy trial. During these smaller trials, an extensive list of polymorphisms from candidate genes, immunological genes and HLA antigens would be tested for possible associations. At this early stage, genome wide screening—and correction for the number of tests performed—would not be productive. The candidate list is small and more focused. The efficacy PGX experiment is designed to compare patients who met the proposed clinical endpoints against patients who did not. In this way early hypotheses could be incorporated into Phase III registration studies and, if re-confirmed, provide more information for targeting therapy.  Read more.

Click here to log in.

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

Reverse Informatics logo
The Fourth Paradigm of Science
Sponsored by Reverse Informatics


liaison logo
Managing and Integrating Clinical Trial Data:
A Challenge for Pharma and their CRO Partners
Sponsored by Liaison Healthcare Informatics


Life Science Webcasts & Podcasts

medidata_podcast_Sites and Sponsors: Mending Bridges over Troubled Waters  
Sites and Sponsors: Mending Bridges over Troubled Waters
Sponsored by Medidata Solutions Worldwide

This podcast brings together two industry leaders to focus on the issues that divide sponsors and sites. On the one hand sites and sponsors unite in advancing better health care through a common passion for developing better drugs. Yet some issues divide them and bridges need to be built or mended to advance the highest levels of cooperation, coordination and success in clinical trials. Listen as the key issues are debated from the site and the sponsor side and new methods and technology are advanced that offer near-term and lasting solutions.

• Common ground in reaching agreement on a budget

• Improving the pace of agreement on budgets and contracts

• Processes for payment to sites on a timely basis

Listen Now  

More Podcasts

Job Openings

For reprints and/or copyright permission, please contact  Jay Mulhern, (781) 972-1359, jmulhern@healthtech.com.